Layton Elly, Vaisey Alaina, Goller Jane L, Coombe Jacqueline, Temple-Smith Meredith, Hocking Jane
From the Melbourne School of Population & Global Health.
Department of General Practice, University of Melbourne, Melbourne, Australia.
Sex Transm Dis. 2020 Dec;47(12):790-797. doi: 10.1097/OLQ.0000000000001260.
The majority of research on patient-delivered partner therapy (PDPT) has focused on its impact on reinfections. This study aimed to systematically review the evidence regarding the acceptability of PDPT by patients and partners for chlamydia infection.
Three electronic databases were searched in March 2019 using terms related to PDPT. Studies were included if they reported on patient or partner acceptance of PDPT for chlamydia and were conducted in high-income countries. Actual and perceived acceptabilities of PDPT were assessed.
Thirty-three studies were included: 24 quantitative, 3 qualitative, and 6 mixed methods. Most were clinic based. Quantitative data showed that participants' perceived willingness to give PDPT to their partner(s) ranged from 44.7% to 96.3% (median, 84%), and 24% to 71% (median, 65%) of people who offered PDPT for their partner(s) accepted it. Partners' perceived willingness to accept ranged from 42.7% to 67% (median, 62%), and actual acceptance ranged from 44.7% to 80% (median, 77%). Those in longer-term relationships were generally more likely to accept PDPT; however, beyond this, we identified few clear trends. Qualitative studies found that convenience of PDPT and assurance of partner treatment were benefits, whereas partners not seeing a health care professional was viewed as a downside. Packaging that appeared legitimate and coaching on delivering PDPT were facilitators.
Because patients bear responsibility for the success of PDPT, this information is crucial in clinical settings. Acceptance, perceived and real, of PDPT was generally high. Patients are best placed to determine whether PDPT is appropriate for them, and it should be offered as an option.
大多数关于患者主导的性伴治疗（PDPT）的研究都集中在其对再感染的影响上。本研究旨在系统回顾关于衣原体感染患者及其性伴对PDPT可接受性的证据。
2019年3月，使用与PDPT相关的术语检索了三个电子数据库。纳入的研究需报告衣原体感染患者或其性伴对PDPT的接受情况，且研究在高收入国家进行。评估了PDPT的实际可接受性和感知可接受性。
共纳入33项研究：24项定量研究、3项定性研究和6项混合方法研究。大多数研究以诊所为基础。定量数据显示，参与者认为愿意将PDPT提供给其性伴的比例在44.7%至96.3%之间（中位数为84%），提供PDPT的人中有24%至71%（中位数为65%）的性伴接受了PDPT。性伴认为愿意接受的比例在42.7%至67%之间（中位数为62%），实际接受比例在44.7%至80%之间（中位数为77%）。处于长期关系中的人通常更有可能接受PDPT；然而，除此之外，我们几乎没有发现明显的趋势。定性研究发现，PDPT的便利性和性伴治疗的保证是其优点，而性伴不看医疗专业人员则被视为缺点。看起来正规的包装以及PDPT实施指导是促进因素。
由于患者对PDPT的成功负有责任，这些信息在临床环境中至关重要。PDPT的感知可接受性和实际可接受性总体较高。患者最有能力决定PDPT是否适合他们，应将其作为一种选择提供给患者。
